How many companies in City of St. Louis received FDA inspections in December 2023?

How many companies in City of St. Louis received FDA inspections in December 2023?
Vid Desai FDA’s Chief Information Officer — Official Website
0Comments

There was one company in the City of St. Louis, Missouri, that received an FDA inspection in December 2023, according to reports from the U.S. Food and Drug Administration (FDA).

This is a 66.7% decrease from the number of companies inspected in the previous month, when three companies were inspected through three inspections.

The only company inspected was involved in the Drugs sector.

The company should take voluntary action to correct their managing operations.

The FDA routinely inspects facilities across the nation to determine if the workplace and their products are compliant with FDA-regulated laws and regulations implemented to improve overall public health. Inspection results are then disclosed publicly.

The FDA is a government agency that is primarily responsible for monitoring the production and distribution of human and animal drugs, biological products, medical supplies and tobacco products for safety quality, according to its website.

Companies Located in City of St. Louis and Their Inspection Results
Company Name Area of Business Inspection Date Result
Patheon Biologics, LLC Drugs 12/08/2023 Voluntary Action Indicated (VAI)


Related

Laura V. Swett, Chairman of Federal Energy Regulatory Commission (FERC)

Cheapest premium gas in St. Louis city reach $4.39 in week ending May 9

For the week ending May 9, the lowest reported price of premium gas in St. Louis city stood at $4.39 per gallon.

Laura V. Swett, Chairman of Federal Energy Regulatory Commission (FERC)

St. Louis city saw lowest price for regular gas at $3.69 in week ending Apr. 25

The lowest price for a gallon of regular gas in St. Louis city during the week ending Apr. 25 was $3.69, according to customer reports to GasBuddy.

Peter Mihalick, Public Policy VP for AMIA

Public Policy VP Mihalick scrutinizes 340B program for ‘shortchanging patients to increase profits,’ as 340B concerns grow in Missouri

Peter Mihalick of the American Medical Informatics Association warned that the 340B Drug Pricing Program may incentivize nonprofit hospitals to prioritize profits over patient savings, as scrutiny over the program continues to grow.

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from St. Louis Reporter.